IDEXX Laboratories

IDEXX Laboratories reiterated long-term targets of >10% organic revenue growth and >15% EPS growth, driven by recurring revenue and an underpenetrated $45bn veterinary diagnostics market. Management emphasized product momentum—expanding the inVue Dx cytology platform, adding Catalyst tests, broadening Cancer Dx into a multi-cancer panel and developing MultiQ Dx—while expecting ~1.5% fewer veterinary visits in H2 but higher diagnostic utilization from an aging, more medicalized pet population. The company targets a full-year comparable operating margin above 32%, plans continued commercial expansion and R&D investment, and prioritizes organic growth with excess capital returned via share repurchases. » Mere på finance.yahoo.com

IDEXX presented a growth plan at the Morgan Stanley Global Healthcare Conference that offsets a near‑term slight decline in veterinary visits (expected H2‑2026: −1.5 to −2%) with long‑term tailwinds from new diagnostic products and commercial expansion. Management highlighted an "exceptional" Q2, raised the annual guidance, and reaffirmed long‑term targets of over 10% organic growth and more than 15% EPS growth. Key drivers are new products such as Cancer Dx, inVue Dx and the planned MultiQ Dx platform, along with investments in sales, software and international expansion; the operating margin for 2026 is expected to exceed 32%. IDEXX emphasizes high recurring revenue in reference labs, strong test demand, and the use of free cash flow for reinvestment and share buybacks. » Mere på de.investing.com

In its Q2 2026 investor letter, Baron Focused Growth Fund named IDEXX Laboratories as a key health-care holding, citing its leadership in veterinary diagnostics and benefits from pandemic-driven pet ownership and aging pet demographics. The fund, which returned 13.26% in Q2 while trailing the Russell 2500 Growth, views IDEXX as a competitively advantaged business within a diversified, growth-oriented portfolio. IDEXX closed at $562.20 on August 19, 2026 with a $44.29 billion market cap and has a one‑month return of 4.23% and a 52‑week decline of 11.19%. » Mere på finance.yahoo.com

IDEXX Laboratories reported Q2 revenue up about 10% (9% organic) and EPS of $4.27, an 18% increase, driven by companion animal diagnostics and other businesses. The company placed 1,602 inVue Dx analyzers in the quarter, remains on track for ~5,500 placements in 2026, and said Cancer Dx surpassed 10,000 ordering clinics with broader FNA rollout planned by year-end. Reported operating margin was 35%, free cash flow totaled $323 million for the quarter, and IDEXX repurchased $332 million of shares. Management raised full-year 2026 guidance to $4.70–$4.745 billion revenue, comparable EPS $14.69–$14.94, and free-cash-flow conversion of 90%–100% of net income. » Mere på finance.yahoo.com

Jensen Investment Management added IDEXX Laboratories to its Q2 2026 Quality Growth Equity Strategy, citing a large installed instrument base, ~99% customer retention and about 90% recurring revenue. The fund highlighted IDEXX's R&D-driven barriers, low debt, and defensive exposure via veterinary diagnostics and practice software, saying weak 2026 share performance created a favorable entry point. Near-term pet spending may be pressured by inflation, but Jensen expects consistent revenue and above-cost-of-capital returns over the long term. » Mere på finance.yahoo.com